glp-1 receptor agonists and cardiovascular outcome trials an update cardiorenal outcomes in type 2 diabetes: updated meta-analysis of eight CVOTs | Diabetology Table 1 from Cardiovascular Effects
Description
By indication, type 2 diabetes accounted for 87.36% revenue in 2025, but obesity and weight-management prescriptions are forecast to grow at 11.57% CAGR to 2031
It is in the incretin mimic class of peptides
The mechanism behind this is straightforward
Zealand Pharma: ZP 8396 (Amylin analog) [65] In a randomized, double-blinded, placebo-controlled study, an amylin analog, ZP-8396, was investigated in a cohort of 56 male subjects, both lean and obese individuals
Add TheStreet as a Preferred Source by clicking here.
Exenatide- Long-Acting Agents Later, an extended-release formulation of exenatide was developed and given once a week
